Evolus, Inc. (NASDAQ:EOLS) Director Sells $167,415.12 in Stock

Evolus, Inc. (NASDAQ:EOLS) Director Karah Herdman Parschauer sold 12,888 shares of Evolus stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $12.99, for a total transaction of $167,415.12. Following the transaction, the director now directly owns 32,183 shares in the company, valued at approximately $418,057.17. This represents a 28.59 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Evolus Trading Up 1.9 %

Shares of NASDAQ:EOLS opened at $13.20 on Friday. The company’s 50-day moving average price is $13.13 and its two-hundred day moving average price is $13.97. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. Evolus, Inc. has a one year low of $9.25 and a one year high of $17.82. The stock has a market capitalization of $839.35 million, a PE ratio of -14.51 and a beta of 1.28.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Barclays boosted their price objective on shares of Evolus from $22.00 to $25.00 and gave the company an “overweight” rating in a research report on Wednesday, March 5th. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price objective on shares of Evolus in a research report on Wednesday, March 5th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Evolus in a research report on Wednesday, March 5th.

Institutional Investors Weigh In On Evolus

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Tang Capital Management LLC lifted its position in Evolus by 3.1% during the 4th quarter. Tang Capital Management LLC now owns 4,997,399 shares of the company’s stock worth $55,171,000 after buying an additional 150,000 shares in the last quarter. Nantahala Capital Management LLC lifted its position in Evolus by 10.8% during the 4th quarter. Nantahala Capital Management LLC now owns 3,130,149 shares of the company’s stock worth $34,557,000 after buying an additional 305,300 shares in the last quarter. Caligan Partners LP lifted its position in Evolus by 22.7% during the 4th quarter. Caligan Partners LP now owns 2,692,388 shares of the company’s stock worth $29,724,000 after buying an additional 498,900 shares in the last quarter. Millennium Management LLC lifted its position in Evolus by 29.1% during the 4th quarter. Millennium Management LLC now owns 1,368,423 shares of the company’s stock worth $15,107,000 after buying an additional 308,753 shares in the last quarter. Finally, Boothbay Fund Management LLC lifted its position in Evolus by 30.9% during the 4th quarter. Boothbay Fund Management LLC now owns 1,287,767 shares of the company’s stock worth $14,217,000 after buying an additional 304,065 shares in the last quarter. 90.69% of the stock is owned by institutional investors.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.